Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial

PURPOSE: Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Escudier, Bernard, Powles, Thomas, Motzer, Robert J., Olencki, Thomas, Arén Frontera, Osvaldo, Oudard, Stephane, Rolland, Frederic, Tomczak, Piotr, Castellano, Daniel, Appleman, Leonard J., Drabkin, Harry, Vaena, Daniel, Milwee, Steven, Youkstetter, Jillian, Lougheed, Julie C., Bracarda, Sergio, Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804840/
https://ncbi.nlm.nih.gov/pubmed/29309249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.7352
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados